Different metabolism of vitamin D2/D3 in epileptic patients treated with phenobarbitone/phenytoin.
Serum concentrations of vitamin D metabolites were measured before and during treatment with either vitamin D2 or vitamin D3, 4000 IU per day for 24 weeks, in 22 epileptic outpatients receiving phenobarbitone/phenytoin. The serum concentration of total 1,25(OH)2D did not change during the treatment period in any of the treatment groups. On the other hand, in the vitamin D2 group, serum 25(OH)D2, total 25(OH)D, and 24,25(OH)2D increased significantly during the trial, whereas serum concentrations of the vitamin D3 metabolites were unchanged. In the vitamin D3 group, serum concentrations of the vitamin D3 metabolites increased significantly, whereas the vitamin D3 metabolite levels remained unchanged. However, vitamin D3 treatment resulted in a 2-4-fold greater increase in serum concentrations compared to vitamin D2 treatment. Treatment with vitamin D2 and vitamin D3 in the same dose in IU results in considerably different serum concentrations of the vitamin D metabolites.
D015650:24,25-Dihydroxyvitamin D 3; D015652:25-Hydroxyvitamin D 2; D000328:Adult; D000368:Aged; D002112:Calcifediol / Q000378:metabolism; D002118:Calcium / Q000378:metabolism; D002762:Cholecalciferol / Q000378:metabolism*; D004100:Dihydroxycholecalciferols / Q000378:metabolism; D004827:Epilepsy / Q000188:drug therapy* / Q000378:metabolism; D004872:Ergocalciferols / Q000031:analogs & derivatives / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010634:Phenobarbital / Q000627:therapeutic use*; D010672:Phenytoin / Q000627:therapeutic use*
D004100:Dihydroxycholecalciferols; D004872:Ergocalciferols; D002762:Cholecalciferol; D015652:25-Hydroxyvitamin D 2; D015650:24,25-Dihydroxyvitamin D 3; D010672:Phenytoin; D002112:Calcifediol; C026032:25,26-dihydroxycholecalciferol; D002118:Calcium; D010634:Phenobarbital